{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:52:53Z","timestamp":1790603573438,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T00:00:00Z","timestamp":1746835200000},"content-version":"vor","delay-in-days":129,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Mediators of Inflammation"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by a reduced platelet count, resulting in bleeding risks and compromised quality of life. Advances in understanding ITP pathogenesis have revealed critical roles for spleen tyrosine kinase (Syk) and Bruton\u2019s tyrosine kinase (BTK) in Fc receptor (FcR)\u2010mediated immune pathways, which are central to autoantibody production and platelet destruction. We sought to evaluate the efficacy and safety of Syk and BTK inhibitors in the management of ITP. PubMed\/Medline, Scopus, and Web of Science databases were systematically searched up to July 28, 2024. Clinical studies with available full\u2010text in English were included. Fostamatinib, an FDA\u2010approved Syk inhibitor, has shown efficacy in enhancing platelet counts and reducing bleeding events in refractory ITP patients. Among the newer Syk inhibitors, sovleplenib demonstrated rapid and sustained platelet increases in clinical trials, with an 80% response rate at the 300\u2009mg dosage and a favorable safety profile. Additionally, BTK inhibitors, including rilzabrutinib and orelabrutinib, have shown potential in clinical trials, offering increased platelet stability and favorable safety profiles in ITP cases. Syk and BTK inhibitors hold potential as targeted therapies for refractory ITP, with evidence supporting their ability to improve clinical outcomes and enhance patient quality of life. Continued research is warranted to optimize these therapies and confirm their long\u2010term efficacy and safety in diverse patient populations.<\/jats:p>","DOI":"10.1155\/mi\/5578929","type":"journal-article","created":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:49:40Z","timestamp":1746848980000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Safety of Syk and BTK Inhibitors in Immune Thrombocytopenia: A Comprehensive Review of Emerging Evidence"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4327-8814","authenticated-orcid":false,"given":"Amirhossein","family":"Heidari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4419-0673","authenticated-orcid":false,"given":"Amirhossein Shahbazi","family":"Mazid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7450-1596","authenticated-orcid":false,"given":"Mohammad","family":"Behroozfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5576-998X","authenticated-orcid":false,"given":"Negar","family":"Ghotbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9043-2228","authenticated-orcid":false,"given":"Fatemeh","family":"Fathabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2809-3091","authenticated-orcid":false,"given":"Sara","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7259-4926","authenticated-orcid":false,"given":"Nazila","family":"Heidari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,10]]},"reference":[{"key":"e_1_2_14_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2013.03.001"},{"key":"e_1_2_14_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-578336"},{"key":"e_1_2_14_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"e_1_2_14_4_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.613192"},{"key":"e_1_2_14_5_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7965930"},{"key":"e_1_2_14_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm6020016"},{"key":"e_1_2_14_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1810479"},{"key":"e_1_2_14_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102342"},{"key":"e_1_2_14_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2024.132417"},{"key":"e_1_2_14_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24234"},{"key":"e_1_2_14_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19068"},{"key":"e_1_2_14_12_2","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-6-13"},{"key":"e_1_2_14_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0000000000000612"},{"key":"e_1_2_14_14_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.248385"},{"key":"e_1_2_14_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm921"},{"key":"e_1_2_14_16_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.115634"},{"key":"e_1_2_14_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00139-X"},{"key":"e_1_2_14_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00034-0"},{"key":"e_1_2_14_19_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.662223"},{"key":"e_1_2_14_20_2","doi-asserted-by":"publisher","DOI":"10.37247\/PAMED4ED.4.22.14"},{"key":"e_1_2_14_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.4.942.942"},{"key":"e_1_2_14_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"e_1_2_14_23_2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2018.33.e142"},{"key":"e_1_2_14_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24358"},{"key":"e_1_2_14_25_2","first-page":"57","article-title":"Anti-RhD Immunoglobulin in the Treatment of Immune Thrombocytopenia","volume":"3","author":"Cheung E.","year":"2009","journal-title":"Biologics: Targets and Therapy"},{"key":"e_1_2_14_26_2","first-page":"14","article-title":"Anti-D: Mechanisms of Action","volume":"35","author":"Ware R. E.","year":"1998","journal-title":"Seminars in Hematology"},{"key":"e_1_2_14_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.8.2689"},{"key":"e_1_2_14_28_2","first-page":"23","article-title":"Efficacy, Safety, and Dose Response of Intravenous Anti-D Immune Globulin (WinRho SDF) for the Treatment of Idiopathic Thrombocytopenic Purpura in Children","volume":"35","author":"Freiberg A.","year":"1998","journal-title":"Seminars in Hematology"},{"key":"e_1_2_14_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2022.2131751"},{"key":"e_1_2_14_30_2","doi-asserted-by":"crossref","unstructured":"KuterD. J. BusselJ. B. andGhanimaW. et al.Rilzabrutinib versus Placebo in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia: LUNA 3 Phase III Study Therapeutic Advances in Hematology 2023 14 https:\/\/doi.org\/10.1177\/20406207231205431.","DOI":"10.1177\/20406207231205431"},{"key":"e_1_2_14_31_2","unstructured":"KuterD. J. EfraimM. andMayerJ. et al.Rilzabrutinib an Oral BTK Inhibitor in Immune Thrombocytopenia The New England Journal of Medicine 386 no. 2022 1421\u20131431."},{"key":"e_1_2_14_32_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012044"},{"key":"e_1_2_14_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27303"},{"key":"e_1_2_14_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s44337-024-00008-8"},{"key":"e_1_2_14_35_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042163"},{"key":"e_1_2_14_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri2765"},{"key":"e_1_2_14_37_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm201271b"},{"key":"e_1_2_14_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000574"},{"key":"e_1_2_14_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.111827"},{"key":"e_1_2_14_40_2","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26164907"},{"key":"e_1_2_14_41_2","doi-asserted-by":"publisher","DOI":"10.3390\/jox13010005"},{"key":"e_1_2_14_42_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2004-835676"},{"key":"e_1_2_14_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.6.2385"},{"key":"e_1_2_14_44_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001130"},{"key":"e_1_2_14_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e22912"},{"key":"e_1_2_14_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm300035p"},{"key":"e_1_2_14_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-166439"},{"key":"e_1_2_14_48_2","article-title":"The Pharmaceutical Industry in 2018, An Analysis of FDA Drug Approvals From the Perspective of Molecules","volume":"24","author":"GdlT B.","year":"2019","journal-title":"Molecules"},{"key":"e_1_2_14_49_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01135-0"},{"key":"e_1_2_14_50_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.109058"},{"key":"e_1_2_14_51_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05824-7"},{"key":"e_1_2_14_52_2","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2318345"},{"key":"e_1_2_14_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2011.04470.x"},{"key":"e_1_2_14_54_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2009.03451.x"},{"key":"e_1_2_14_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25125"},{"key":"e_1_2_14_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60959-2"},{"key":"e_1_2_14_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15573"},{"key":"e_1_2_14_58_2","unstructured":"RyanC. Cevidoplenib Elicits Platelet Responses in Persistent or Chronic Immune Thrombocytopenia European Hematology Association Congress 2023."},{"key":"e_1_2_14_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260"},{"key":"e_1_2_14_60_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-04-748707"},{"key":"e_1_2_14_61_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-023-01231-w"}],"container-title":["Mediators of Inflammation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/mi\/5578929","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/mi\/5578929","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/mi\/5578929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:19:02Z","timestamp":1773008342000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/mi\/5578929"}},"subtitle":[],"editor":[{"given":"Fumio","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/mi\/5578929"],"URL":"https:\/\/doi.org\/10.1155\/mi\/5578929","archive":["Portico"],"relation":{},"ISSN":["0962-9351","1466-1861"],"issn-type":[{"value":"0962-9351","type":"print"},{"value":"1466-1861","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2025-01-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5578929"}}